Supplementary Figures



Supplementary Figure 1. Cytokine levels in healthy pregnant women and pregnant women with COVID-19. Comparison of cytokines levels of (A)IL-2, (B)TNF- α , (C)TNF- β , (D)IFN- γ , (E)IL-4, (F)IL-5, (G)IL-6, (H)IL-10, (I)IL-17A, (J)IL-17F, (K)IL-22, (L)IL-1 β , (M)IL-8 and (N)IL-12p70 in healthy and COVID-19 positive pregnant women during different periods of pregnancy. Data are shown as mean \pm SEM. Multiple unpaired *t*-tests were used to determine statistical significance. **P* < 0.05; ns, not significant.



Supplementary Figure 2. The ratio and cellularity of different lymphocyte among the HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. The frequency and absolute count of (A-B) T cells, (C-D) CD4⁺ T cells, (E-F) CD56^{bri} NK cells and (G-H) CD56^{dim} NK among the HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. Results are shown as mean \pm SEM. One-way ANOVA was used to determine statistical significance. **P* <0.05, ***P* <0.01, *****P* <0.0001, ns, not significant.



Supplementary Figure 3. ICOS expression in NK cells, $CD4^+$ T and $CD8^+$ T cells among the HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (A-D) The expression of ICOS on (A) $CD56^{bri}$ NK cells, (B) $CD56^{dim}$ NK cells, (C) $CD4^+$ T and (D) $CD8^+$ T cells in HC, COVID-19, PHC, PCOVID-19 and PConvalescent group. Results are shown as mean \pm SEM. One-way ANOVA was conducted. * *P* <0.05; ****P* <0.001; ns, not significant.



Supplementary Figure 4. The level of cytokine secretion and proliferation ability of NK cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (A-C) The expression of (A) CD107a (B) IFN- γ (C) Ki67 on CD56^{bri} NK cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (D-F) The expression of (D) CD107a (E) IFN- γ (F) Ki67 on CD56^{dim} NK cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. Results are shown as mean ± SEM. One-way ANOVA was used to determine statistical significance. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001; ns, not significant.



Supplementary Figure 5. The level of cytokine secretion and proliferation ability of T cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (A-C) The expression of (A) CD107a (B) IFN- γ (C) Ki67 on CD4⁺ T cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (D-F) The expression of (D) CD107a (E) IFN- γ (F) Ki67 on CD8⁺ T cells in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. Results are shown as mean \pm SEM. One-way ANOVA was used to determine statistical significance. **P < 0.01; ***P < 0.001 ****P < 0.001; ns, not significant.



Supplementary Figure 6. Expression of ICOSL among the HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (A) Gating strategy of monocytes, starting with Lin⁻(CD3, CD19, CD20, CD56, CD66b) HLA-DR⁺, and then divided it into three groups as CD14⁺CD16⁻ (classical), CD14⁺CD16⁺ (intermediate) and CD14⁻CD16⁺ (non-classical) monocytes. (B-D) The proportion of (A) CD14⁺CD16⁻ classical monocytes, (C) CD14⁻CD16⁺ non-classical monocytes and (D) CD14⁺CD16⁺ intermediate in HC group, COVID-19 group, PHC group, PCOVID-19 group and PConvalescent group. (E-G) The expression of ICOSL in (E) CD14⁺CD16⁻ classical monocytes, (F) CD14⁻CD16⁺ non-classical monocytes and (G) CD14⁺CD16⁺ intermediate in HC group, COVID-19 group, Results are shown as mean ± SEM. One-way ANOVA was used to determine statistical significance. **P*< 0.05; ns, not significant.